Ask AI
ProCE Banner Activity

Novel Frontline Maintenance Therapy Approaches and Targeted Therapies in Lung Cancers: Key Data From the 2025 World Conference on Lung Cancer

Conference Coverage
Clinical Thought

This commentary reviews key data presented at the 2025 World Conference on Lung Cancer that may reshape frontline maintenance strategies in extensive-stage small-cell lung cancer and targeted treatment paradigms in non-small-cell lung cancer. 

Released: February 16, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Jazz Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc.

Target Audience

This activity is intended for oncologists, nurses, physician associates, pharmacists, and other healthcare professionals caring for patients with lung cancers. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate recently presented data, as appropriate and guided by expert recommendations, into the treatment of patients with lung cancers to improve outcomes and quality of life

Disclosure

Primary Author

John Heymach, MD, PhD: advisor: 23andMe, AstraZeneca, Bayer, BioNTech AG, Boehringer Ingelheim, Bristol Myers Squibb, Curios Science, DAVA Oncology, EMD Serono, IDEOlogy Health, Intellisphere, InxMed (Hong Kong) Limited, Janssen, Jazz, Lilly, Mirati, ModeX, OncoHost, Ottimo, Pfizer, Regeneron, Remunity Therapeutics, Synthekine, Takeda; researcher: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Mirati, Takeda; owner: Tenaci-T Therapeutics; licensing/royalties: Spectrum.

Solange Peters, MD, PhD: consultant/advisor/speaker: AbbVie, Amgen, Arcus, AstraZeneca, Bayer, BeiGene, BioNTech, BerGenBio, Bicycle Therapeutics, Biocartis, BioInvent, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, F-Star, Foundation Medicine, Genmab, Genzyme, Gilead, GSK, Hutchmed, Illumina, Incyte, Ipsen, iTeos, Janssen, Lilly, Merck Sharp & Dohme, Merck Serono, Novartis, Novocure, Nuvation Bio, Nuvalent, Nykode, PharmaMar, Promontory, Pfizer, Qlucore, Regeneron, Roche/Genetech, Sanofi, Takeda, Zymeworks; researcher (paid to institution): Amgen, Arcus, AstraZeneca, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, GSK, iTeos, Lilly, Merck Sharp & Dohme, Mirati, Pharma Mar, Pfizer, Promontory, Roche/Genentech.